PATENT CLAIM ANALYSIS

Application Number: 15882924
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-09
Patent Classification: ["514", "252160"]

Abstract:
The present invention relates to pharmaceutical compounds, compositions and methods, especially as they are related to compositions and methods for the treatment and/or prevention of a proliferation disorder, a cancer, a tumor, an inflammatory disease, an autoimmune disease, psoriasis, dry eye or an immunologically related disease, and in some embodiments diseases or disorders related to the dysregulation of kinase such as, but not limited to, EGFR (including HER), Alk, PDGFR, BLK, BMX/ETK, FLT3(D835Y), ITK, TEC, TXK, BTK, or JAK, and the respective pathways.

Claim (Index 1):
A compound of Formula (Ia): wherein R 1  is H, or\n NR c R d  wherein\n R c  is H, C 1-4  alkyl, C 1-4  alkenyl, or 3-7 member cyclic ring, said C 1-4  alkyl, C 1-4  alkenyl, or 3-7 member cyclic ring being optionally substituted with OZ or NR 11 R 12 , wherein Z, R 11 , R 12  are independently H or C 1-4  alkyl, or said 3-7 member cyclic ring being optionally substituted with C 1-4  alkyl that is further optionally substituted with OZ or NR 11 R 12 , wherein Z, R 11 , R 12  are independently H or C 1-4  alkyl, or said 3-7 member cyclic ring being optionally substituted with SO 2 (CH 2 ) q H, wherein q is 1-4, or said 3-7 member cyclic ring being optionally substituted with C 1-4  alkyl that is further optionally substituted with SO 2 (CH 2 ) q H, wherein q is 1-4, or said 3-7 member cyclic ring being optionally substituted with R 8 CO, wherein R 8  is C 1-4  alkyl, and \n R d  is H, C 1-4  alkyl, C 1-4  alkenyl, or 3-7 member cyclic ring, said C 1-4  alkyl, C 1-4  alkenyl or 3-7 member cyclic ring being optionally substituted with OZ or NR 11 R 12 , wherein Z, R 11 , R 12  are independently H or C 1-4  alkyl; or \n \n 3-7 member cyclic ring substituted with R a  wherein R a  is C 1-8  alkyl optionally substituted with halo, C 1-4  alkoxy or SO 2 (CH 2 ) q H, wherein q is 1-4; or \n O(CH 2 ) m SO 2  (CH 2 ) n H, wherein m is 1-4 and n is 1-4; \n R 2  is absent, H, halo, C 1-4  alkyl, C 1-4  alkoxy, or alkylamine (NR 11 R 12 ), wherein R 11  and R 11  are independently H or C 1-4  alkyl; R 3  is H, hydroxyl, halo, C 1-4  alkyl, C 1-4  alkoxy, or alkylamine (NR 11 R 12 ), wherein R 11  and R 12  are independently H or C 1-4  alkyl; R 5  is absent, H, halo, C 1-4  alkyl, C 1-4  alkoxy, or alkylamine (NR 11 R 12 ), wherein R 11  and R 12  are independently H or C 1-4  alkyl; R 6  is H, halo, C 1-4  alkyl, C 1-4  alkoxy; or alkylamine (NR 11 R 12 ), wherein R 11  and R 12  are independently H or C 1-4  alkyl; R 7  is H, halo, C 1-4  alkyl, C 1-4  alkoxy, or alkylamine (NR 11 R 12 ), wherein R 11  and R 12  are independently H or C 1-4  alkyl; R 9  is H, hydroxyl, halo, C 1-4  alkyl, C 1-4  alkoxy, or alkylamine (NR 11 R 12 ), wherein R 11  and R 12  are independently H or C 1-4  alkyl; R 10  is H, hydroxyl, halo, C 1-4  alkyl, C 1-4  alkoxy, or alkylamine (NR 11 R 12 ), wherein R 11  and R 12  are independently H or C 1-4  alkyl; or R 1  and R 5  are part of 3-7 member cyclic ring, said 3-7 member cyclic being optionally substituted with C 1-4  alkyl optionally substituted with OZ or NR 11 R 12  wherein Z, R 11  and R 12  are independently H or C 1-4  alkyl, or said 3-7 member cyclic being optionally substituted with R 8 CO, wherein R 8  is C 1-4  alkyl, or said 3-7 member cyclic being optionally substituted with SO 2 (CH 2 ) q H, wherein q is 1-4; or R 1  and R 2  are part of 3-7 member cyclic ring, optionally substituted with C 1-4  alkyl, said C 1-4  alkyl further optionally substituted with halo, OZ, or NR 11 R 12  wherein Z, R 11  and R 12  are independently H or C 1-4  alkyl, or one or more members of said 3-7 member cyclic ring is optionally part of a carbonyl group or a sulfonyl group; or R 2  and R 6  are part of 3-7 member cyclic ring, optionally substituted with C 1-4  alkyl optionally substituted with OZ or NR 11 R 12  wherein Z, R 11  and R 12  are independently H or C 1-4  alkyl; R 4  is C 2  alkenyl optionally substituted with C 1-4  alkyl, \u2014CH 2 OCH 3 , or \u2014CH 2 N(CH 3 ) 2 ; X is O, C 1-4  alkyl optionally substituted with halo, or NR b , wherein R b  is H, or C 1-8  alkyl optionally substituted with halo; Y is C, CH optionally substituted with halo, or N; A is C, CH optionally substituted with halo or N; and wherein at least one of R 2 , R 3 , R 5  and R 6  is not H; or a pharmaceutically acceptable salt thereof.

Metadata:
- Claim Count in Document: 66.0
- Percentile: 86.0
- Lexical Diversity: 1.68182
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14329890', '16068559', '13436910', '14712794', '13436963']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7798879350010831
- 35 USC 102 Novelty (BERT): 0.5568991045704127
- Combined Prediction Score: 0.7575890519580161
- Mean Citation Score: 306.409536
- Max Citation Score: 426.96307
- Similarity Product: 355.3965113406217

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test